Allergan’s Botox trade secrets win at the ITC underlines its growing importance in life sciences IP disputes
Victory for the US company and its Korean partner Medytox shows how Section 337 proceedings are becoming a vital enforcement tool for pharma and biotech rights owners
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.
Subscribe now